Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

Submitted by admin on July 31, 2019 - 10:24am

Source:

Endpoints

News Tags:

Novartis

Vas Narasimhan

M&A

Pharma CEOs

Headline:

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

snippet:

Puzzling out the M&A and deal strategy at Novartis has been one of the most popular parlor games in biopharma. CEO Vas Narasimhan, an upbeat guy, has enjoyed a good streak of new drug approvals. And since being named to the post in the fall of 2017, he’s delighted in a series of small to mid-sized bolt-on deals — mostly for cash — that’s kept everyone buzzing about what he’ll turn to next.

Search form

You are here

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy